Axsome Therapeutics Valuation

Is 19X undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 19X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 19X (€83.42) is trading below our estimate of fair value (€1423.82)

Significantly Below Fair Value: 19X is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 19X?

Other financial metrics that can be useful for relative valuation.

19X key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.4x
Enterprise Value/EBITDA-16.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 19X's PS Ratio compare to its peers?

The above table shows the PS ratio for 19X vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.4x
DMP Dermapharm Holding
1.5x3.8%€1.7b
BAYN Bayer
0.4x1.4%€24.0b
93M1 MPH Health Care
0.9x-60.2%€97.6m
PSG PharmaSGP Holding
2.6x7.0%€297.4m
19X Axsome Therapeutics
15x38.4%€4.3b

Price-To-Sales vs Peers: 19X is expensive based on its Price-To-Sales Ratio (15x) compared to the peer average (1.4x).


Price to Earnings Ratio vs Industry

How does 19X's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 19X is expensive based on its Price-To-Sales Ratio (15x) compared to the European Pharmaceuticals industry average (3.2x).


Price to Sales Ratio vs Fair Ratio

What is 19X's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

19X PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15x
Fair PS Ratio12.7x

Price-To-Sales vs Fair Ratio: 19X is expensive based on its Price-To-Sales Ratio (15x) compared to the estimated Fair Price-To-Sales Ratio (12.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 19X forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€83.42
€115.86
+38.9%
18.2%€166.45€92.47n/a17
Nov ’25€82.46
€115.86
+40.5%
18.2%€166.45€92.47n/a17
Oct ’25€80.00
€113.14
+41.4%
18.2%€162.61€90.34n/a17
Sep ’25€79.68
€113.05
+41.9%
18.6%€163.69€90.94n/a16
Aug ’25€79.32
€113.96
+43.7%
20.0%€174.53€87.27n/a17
Jul ’25€75.42
€113.80
+50.9%
20.5%€174.72€89.20n/a16
Jun ’25€67.72
€115.00
+69.8%
20.5%€176.83€90.28n/a16
May ’25€67.80
€114.43
+68.8%
21.3%€177.21€86.74n/a16
Apr ’25€73.42
€112.34
+53.0%
22.5%€176.13€83.43n/a16
Mar ’25€74.56
€111.08
+49.0%
22.1%€165.89€82.94n/a15
Feb ’25€82.56
€110.92
+34.4%
23.1%€166.19€83.10n/a14
Jan ’25€71.18
€105.27
+47.9%
26.3%€164.88€73.28n/a13
Dec ’24€62.06
€106.77
+72.0%
27.4%€168.46€74.87n/a12
Nov ’24€60.82
€110.02
+80.9%
26.0%€170.87€79.74€82.4612
Oct ’24€68.38
€108.74
+59.0%
25.7%€167.89€78.35€80.0012
Sep ’24€73.82
€105.96
+43.5%
26.0%€163.94€73.77€79.6812
Aug ’24€70.38
€102.21
+45.2%
32.4%€171.91€53.38€79.3212
Jul ’24€67.00
€104.01
+55.2%
34.2%€183.62€52.33€75.4212
Jun ’24€69.78
€104.33
+49.5%
33.8%€187.14€53.33€67.7213
May ’24€63.94
€97.78
+52.9%
36.7%€181.50€47.19€67.8013
Apr ’24€54.88
€98.77
+80.0%
33.5%€185.30€48.18€73.4216
Mar ’24€64.64
€100.87
+56.0%
34.5%€196.96€48.77€74.5616
Feb ’24€68.00
€100.82
+48.3%
33.8%€193.60€47.94€82.5616
Jan ’24€70.62
€103.00
+45.9%
34.8%€197.80€48.98€71.1815
Dec ’23€67.20
€106.61
+58.7%
35.6%€203.39€50.36€62.0614
Nov ’23€48.94
€101.20
+106.8%
43.5%€212.56€35.43€60.8215

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies